Compare Novartis AG (NVS) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.15 (market cap $3.80B). The key difference: Novartis AG is far larger — about 70.7× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Novartis AG pays a 3.31% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| NVS | VNQI | |
|---|---|---|
Market Cap | $268.57B | $3.80B |
Volume | 1,532,573 | 277,049 |
Sector | Health | — |
52-Week High | $168.62 | $50.76 |
52-Week Low | $121.80 | $41.81 |
Typical Hold Time | 82 Days | 95 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
VNQI trades at $41.82, showing minimal daily movement with a 0.02% gain. Technical indicators signal bearish momentum as moving averages show unanimous selling pressure, though oscillators remain neutral. Recent news highlights a significant 45.9% drop in short interest in September 2026, while the fund continues to offer competitive advantages including exposure to international real estate markets across 30+ countries and a higher dividend yield compared to domestic alternatives.
The ETF faces headwinds from global real estate market volatility but maintains structural strengths through diversification and cost efficiency. Key risks include international economic sensitivity and currency fluctuations, while the reduced short interest suggests some investor confidence. Long-term appeal lies in international real estate exposure and income generation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
